Diagnostic Value of Fetal Echocardiography for Congenital Heart Disease

A Systematic Review and Meta-Analysis

Ya-Fei Zhang, MD, Xian-Ling Zeng, MD, En-Fa Zhao, MD, and Hong-Wei Lu, MD

Abstract: Prenatal diagnosis of fetal congenital heart disease (CHD) has been shown to have a significant effect on prenatal and postnatal management and outcomes. However, the factors influencing its diagnostic accuracy and which section is most adaptive for fetal remain uncertain despite extensive research. The aim of the present study was to evaluate the accuracy of echocardiography for detecting CHD and potential influence factors.

We searched Chinese Biomedical Database (CBM), Medline, ISI Web of Knowledge, the Cochrane Library, and China National Knowledge Infrastructure (CNKI) to identify relevant studies from January 1, 1990 to August 13, 2015.

Overall, the pooled sensitivity, specificity, diagnostic odds ratio, positive likelihood ratio, and negative likelihood ratio were 68.5% (95% confidence interval [CI], 66.8%–70.2%), 99.8% (95% CI, 99.7%–99.8%), 3026.9 (95% CI, 1417.9–6461.8), 659.41 (95% CI, 346.38–1255.3), and 0.246 (95% CI, 0.187–0.324) respectively. The pooled sensitivity of basic cardiac echocardiographic examination (BCEE), extended cardiac echocardiographic examination (ECEE), BCEE plus outflow tract view (BCEE + OTV), BCEE + OTV + 3VTV (BCEE plus outflow tract view plus three vessel and trachea view) for the prenatal diagnosis of CHD were 49.0%, 75.5%, 66.1%, and 83.7% respectively. The pooled sensitivity of the prenatal echocardiographic diagnosis of CHD during the first trimester, second trimester, the second to third trimester were 60.3%, 60.9%, and 77.4%, respectively. The pooled sensitivity of BCEE and ECEE for the prenatal diagnosis of CHD during the second to third trimester was significantly higher than that during the second trimester. The pooled sensitivity of the prenatal echocardiographic diagnosis of CHD for pregnancies with low risk, high risk, low and high risk, and unselected risk were 45.4%, 85.1%, 89.1%, and 66.2%, respectively. The sensitivity analysis was robust and risk level was significant source of heterogeneity. Deek test indicated no potential significant publication bias.

Prenatal ultrasound is a powerful tool for the diagnosis of CHD; however, echocardiography has individual sensitivity for different gestation period, different levels of risk, and different echo-views.

Abbreviations: 3VTV = three vessel and trachea view, BCEE = basic cardiac echocardiographic examination, CBM = Chinese Biomedical Database, CHD = congenital heart disease, CNKI = China National Knowledge Infrastructure, ECEE = extended cardiac echocardiographic examination, OTV = outflow tract view.

INTRODUCTION

The incidence of congenital heart disease (CHD) has been estimated at 6 to 12 per 1000 live births.1 According to the WHO, cardiac defects account for 42% of infant deaths and have become the leading cause of infant mortality.2 The fetal echocardiogram marks the primary tool for the evaluation and detailed diagnosis of fetal cardiovascular pathology from the late first trimester to term. Prenatal detection of CHD may improve the pregnancy outcome of fetuses with specific types of cardiac lesions.3 Accurate prenatal diagnosis offers potential clinical benefit with regard to infant outcome.4 Prenatal detection accuracy has varied widely for CHD.

Some of this variation can be attributed to examiner experience, maternal obesity, transducer frequency, abdominal scars, gestational age, amniotic fluid volume, and fetal position.5,6 Initially, fetal echocardiography included only a 4-chamber view (basic cardiac echocardiographic examination [BCEE]) of the heart, then outflow tract view (OTV) and 3-vessels trachea view (3VTV) were added to increase accuracy of fetal echocardiography. More recently, ECEE, which included the 4-chamber view, the right ventricular outflow tract, the left ventricular outflow tract, and the main pulmonary artery and its branches,7 was used as a specific protocol to identify some minimal defects in utero and provide more detail information on suspicious fetal heart. Several subspecialty organizations have published formal practice guidelines.8–11

However, there was no consensus as how to choose from the 4 protocols for fetal CHD diagnosis according to different gestation period, different levels of risk, even though some comparison studies12–17 have been done on the accuracy among different scan protocols. Buskens et al18 concluded a sensitivity of 4.5% with BCEE in a low-risk populations, whereas Ogge et al15 concluded a sensitivity of 60.3% with BCEE in a low-risk populations. Ott12 concluded a sensitivity of 14.3% with ECEE in a low-risk populations, whereas Abdul-Haium et al17 yielded a sensitivity of 65.8% with ECEE in a low risk. Tegnander et al16 yielded a sensitivity of 56.7% with BCEE + OTV in an
unselected populations during the second trimester, where as Zosmer et al.\textsuperscript{14} yielded a sensitivity of 88.9% with BCEE + OTV in a high-risk population during the second trimester. Previous study\textsuperscript{18} had drawn a systematic review using 5 protocols detection of fetal CHD among unselected, low-, and high-risk populations, and they concluded that the pooled sensitivity of BCEE, BCEE + OTV/3VTV, ECEE, and BCEE + OTV + 3VTV were 52%, 65%, 89%, and 90%, respectively; however, they did not evaluate the sensitivity between prospective studies and retrospective studies, and only English articles were included in the study. Besides, they failed to make comparisons among different stages of pregnancy. Therefore, we decided to carry out a meta-analysis of prospective studies to make a more precise estimation. In the meta-analysis, we evaluated the accuracy of fetal diagnosis and compared sensitivities among different diagnostic protocols, different risk factors, and different stages of pregnancy.

RESULTS

Characteristics of the Included Studies

Initial searches identified 2456 English articles and 1456 Chinese articles. According to the inclusion and exclusion criteria mentioned above, 43 articles (18 Chinese article and 25 English articles) including 50 studies were eligible, with a total of 308,029 fetuses (Fig. 1). A summary of included 50 studies is presented in Table 1,\textsuperscript{7,12–17,19–54} and the diagnostic test parameter of fetal echocardiography for the prenatal diagnosis of CHD is presented in Table 2.\textsuperscript{7,12–14,19–54}

Meta-Analysis

To explore whether any threshold effects existed in our study, we performed a spearman rank correlations of sensitivity against (1-specificity) to detect it. No obvious threshold effects exist in the meta-analysis according to the overall result (Spearman correlation coefficient: 0.041, \(P = 0.777\)). In general, the overall sensitivity and specificity of fetal echocardiography for the prenatal diagnosis of CHD had a moderate sensitivity of 68.5% (95% CI, 66.8%–70.2%) and the high specificity of 99.8% (95% CI, 99.7%–99.8%) (AUC = 0.9924). The SROC curve is shown in Figure 2 with almost the same specificities of nearly 100%. We divided the included studies into 4 sections according to different echo-views: BCEE, ECEE,
| Study/Year | Country       | Maternal Age y | Risk Factors | Gestational Ages | Echo-Views | Fetus, n |
|-----------|---------------|----------------|--------------|-----------------|------------|----------|
| Levi et al, 1991¹⁹ | Belgium       | NP             | Low-risk     | 16–20           | ECEE       | 16,361   |
| Luck, 1992²⁰   | UK            | NP             | Unselected   | 19              | BCEE       | 8523     |
| Vergani et al, 1992²¹ | Italy       | NP             | Unselected   | 18–20           | BCEE       | 9016     |
| Achiron et al, 1992/a²⁷ | Israel     | 25 (18–45)    | Low-risk     | 21 (18–24)      | BCEE       | 5347     |
| Achiron et al, 1992/b²⁷ | Israel     | 25 (18–45)    | Low-risk     | 21 (18–24)      | ECEE       | 5347     |
| Achiron et al, 1994²² | Israel     | NP             | Low-risk     | 13–15           | ECEE       | 660      |
| Kirk et al, 1994²³ | USA          | NP             | Low-risk     | 23 (14–42)      | BCEE       | 5967     |
| Ott, 1995/a²¹² | USA          | NP             | High-risk    | 15–40           | BCEE + OTV | 886      |
| Ott, 1995/b²¹² | USA          | NP             | Low-risk     | 15–40           | BCEE + OTV | 1136     |
| Hsieh et al, 1996²⁴ | Chinese Taipei | NP        | Low- and high-risk | 16–36         | ECEE       | 2485     |
| Buskens et al, 1996³³ | Netherlands | 29 (14–47)    | Low-risk     | 19 (16–24)      | BCEE       | 5319     |
| Zhou et al, 1996²⁵ | PR China     | 28 (24–37)   | High-risk    | 20–40           | ECEE       | 368      |
| Kirk et al, 1997²⁶ | USA          | NP             | Unselected   | 18 (14–42)      | BCEE + OTV | 16,121   |
| Odgers et al, 1997²⁷ | Italy        | NP             | Low-risk     | 19–22           | BCEE       | 8299     |
| Stefos et al, 1999²⁸ | Greece      | NP             | Unselected   | 18–22           | BCEE       | 7236     |
| Zosmer et al, 1999²⁹ | USA          | NP             | High-risk    | 17–22           | BCEE + OTV | 323      |
| Pan et al, 2001³⁰ | PR China     | 22–39          | High-risk    | 20–42           | ECEE       | 900      |
| Comas Gabriel et al, 2002³¹ | Spain      | 17–46          | High-risk    | 14.2 (12–17)    | ECEE       | 334      |
| Ozkutlu et al, 2005³² | Turkey       | 28 (18–42)    | High-risk    | 18–39           | ECEE       | 642      |
| Zhou et al, 2005/a³²³ | PR China     | NP             | High-risk    | 12–17           | BCEE       | 383      |
| Zhou et al, 2005/b³²³ | PR China     | NP             | High-risk    | 12–17           | BCEE + DV  | 383      |
| Liu et al, 2005/a³²³ | PR China     | 26–36         | NP           | 16–40           | ECEE       | 4300     |
| Liu et al, 2005/b³²³ | PR China     | 26–36         | NP           | 16–40           | BCEE       | 4300     |
| Becker et al, 2006³³ | Germany      | 35 (15–46)    | Low- and high-risk | 11–13      | ECEE       | 3094     |
| Oggé et al, 2006/a³²³ | Italy        | NP             | Low-risk     | 18–24           | BCEE       | 6368     |
| Oggé et al, 2006/b³²³ | Italy        | NP             | Low-risk     | 18–24           | BCEE + OTV | 6368     |
| Tegnander et al, 2006³⁶ | Norway       | 29 (15–53)    | Unselected   | 18 (16–22)      | BCEE + OTV | 29,460   |
| Zhu et al, 2006³⁵   | PR China     | 30 (20–48)    | High-risk    | 26.5 (16–42)    | ECEE       | 1788     |
| Plesinac et al, 2007³⁶ | Serbia       | 19–48         | High-risk    | NP              | ECEE       | 517      |
| Chang et al, 2008³⁷ | PR China     | 29 (21–37)    | Unselected   | 20–26           | ECEE       | 1200     |
| Chen et al, 2008³⁸ | PR China     | 16–45         | Low- and high-risk | 16–42      | ECEE       | 17651    |
| Ren et al, 2008/a³⁹ | PR China     | 29 ± 6        | Unselected   | 20–24           | BCEE       | 11544    |
| Ren et al, 2008/b³⁹ | PR China     | 29 ± 6        | Unselected   | 20–24           | BCEE + OTV | 11544    |
| Thangaroopan et al, 2008³⁰ | Canada     | 28            | High-risk    | 21 (16–37)      | ECEE       | 276      |
| Wu et al, 2009/a³⁰¹ | PR China     | 30 (20–40)    | Unselected   | 20–24           | BCEE       | 8025     |
| Wu et al, 2009/b³⁰¹ | PR China     | 30 (20–40)    | Unselected   | 20–24           | BCEE + OTV + 3VT  | 8025     |
| Xu et al, 2009³³² | PR China     | 28 (18–48)    | Unselected   | 18–40           | BCEE + OTV + 3VT  | 4882     |
| Bennasar et al, 2010³³³ | Spain      | 32 (16–43)    | High-risk    | 24 (11–41)      | ECEE       | 342      |
| Huang et al, 2010³³⁴ | PR China     | 22–40         | Low- and high-risk | 21–40      | ECEE       | 6500     |
| Yan et al, 2010³³⁵ | PR China     | 18–43         | Low- and high-risk | 20–41      | BCEE + OTV + 3VT  | 4200     |
| Zhao et al, 2010³³⁶ | PR China     | NP            | Unselected   | 20–40           | ECEE       | 6621     |
| Yagel et al, 2011³³⁷ | Israel       | NP            | Low- and high-risk | 14–24      | ECEE       | 13,101   |
| Abdul Haim et al, 2011³³⁸ | UK          | NP            | Low-risk     | 19–22           | BCEE + OTV | 64,681   |
| Zeng et al, 2011³³⁹ | PR China     | 19–41         | Low- and high-risk | 16–36      | BCEE       | 293      |
| Prats et al, 2012³⁴⁰ | Spain        | 33 (17–55)    | Low-risk     | 11–13           | BCEE + DV  | 9483     |
| Luan et al, 2012³⁴¹ | PR China     | 20–37         | Unselected   | 16–41           | BCEE + OTV + 3VT  | 9237     |
| Wang et al, 2012³⁴² | PR China     | 20–40         | Low- and high-risk | 20–24      | BCEE + OTV + 3VT  | 8481     |
| Wang et al, 2012³⁴³ | PR China     | 17–46         | Unselected   | 15–40           | BCEE + OTV + 3VT  | 3095     |
| Wang et al, 2014³⁴⁴ | PR China     | 20–35         | Unselected   | 18–28           | ECEE       | 1500     |
| Wiechec et al, 2015³⁴⁵ | Poland       | 32.3 (27–40)  | Unselected   | 11–13           | BCEE       | 1084     |

3VT ¼ 3-vessel and trachea view, BCEE ¼ basic cardiac echocardiographic examination, DV ¼ venous duct, ECEE ¼ extended cardiac echocardiographic examination, NP ¼ not provided, OTV ¼ outflow tract view.
**TABLE 2. The Diagnostic Test Parameter of Fetal Echocardiography for the Prenatal Diagnosis of CHD**

| Study/Year          | TP/n | FP/n | FN/n | TN/n | SEN/% | SPE/% | Transducer Frequency |
|---------------------|------|------|------|------|-------|-------|----------------------|
| Levi et al, 1991    | 19   | 154  | 8    | 227  | 40.4  | 99.9  | NP                   |
| Luck, 1992          | 9    | 2    | 16   | 8498 | 36    | 100   | 3.5, 5.0 MHz         |
| Vergani et al, 1992 | 33   | 2    | 14   | 8967 | 70.2  | 100   | 3.5, 5.0 MHz         |
| Achiorn et al, 1992 | 11   | 1    | 12   | 5323 | 47.8  | 100   | 3.5, 5.0 MHz         |
| Achiorn et al, 1992 | 18   | 1    | 5    | 5323 | 78.3  | 100   | 3.5, 5.0 MHz         |
| Achiorn et al, 1994 | 3    | 0    | 6    | 651  | 33.3  | 100   | 6.5, 7.5 MHz         |
| Kirk et al, 1994    | 24   | 1    | 27   | 5915 | 47.1  | 100   | NP                   |
| Ott, 1995           | 10   | 2    | 6    | 868  | 62.5  | 99.8  | NP                   |
| Ott, 1995           | 2    | 12   | 12   | 1110 | 43.3  | 98.9  | NP                   |
| Hsieh et al, 1996   | 67   | 2    | 3    | 2413 | 95.7  | 99.9  | 3.5, 5.0 MHz         |
| Buskens et al, 1996 | 2    | 5    | 42   | 5270 | 4.5   | 99.9  | NP                   |
| Zhou et al, 1996    | 10   | 1    | 1    | 356  | 90.9  | 99.7  | 3 MHz                |
| Kirk et al, 1997    | 73   | 12   | 38   | 15,998 | 65.8   | 99.9  | NP                   |
| Todros et al, 1997  | 6    | 6    | 34   | 8253 | 15    | 99.9  | NP                   |
| Stefos et al, 1998  | 14   | 2    | 17   | 7203 | 45.2  | 100   | 3.5, 7.5 MHz         |
| Zomer et al, 1999   | 32   | 0    | 3    | 296  | 88.9  | 100   | NP                   |
| Pan et al, 2001     | 34   | 43   | 3    | 820  | 92    | 95    | 2.5–3.5 MHz          |
| Comas Gabriel et al | 38   | 0    | 10   | 286  | 79.2  | 100   | NP                   |
| Ozkutlu et al, 2005 | 42   | 0    | 3    | 597  | 93.3  | 100   | 2.5, 5.0 MHz         |
| Zhou et al, 2005    | 18   | 1    | 12   | 352  | 60    | 99.7  | 3.5, 6.9 MHz         |
| Zhou et al, 2005    | 25   | 1    | 5    | 352  | 83.3  | 99.7  | 3.5, 6.9 MHz         |
| Liu et al, 2005     | 46   | 4    | 5    | 4245 | 90.2  | 99.9  | 3.5 MHz              |
| Liu et al, 2005     | 33   | 4    | 18   | 4245 | 64.7  | 99.9  | 3.5 MHz              |
| Becker et al, 2006  | 32   | 0    | 6    | 3056 | 84.2  | 100   | 8.0, 14.0 MHz        |
| Oggé et al, 2006    | 35   | 14   | 23   | 6296 | 60.3  | 99.8  | NP                   |
| Oggé et al, 2006    | 38   | 16   | 20   | 6294 | 65.5  | 99.7  | NP                   |
| Tegnander et al, 2006 | 55 | 1 | 42 | 29362 | 56.7 | 100 | 3.5, 5.0 MHz |
| Zhu et al, 2006     | 35   | 1    | 3    | 1749 | 92.1  | 99.9  | 3.5, 5.0 MHz         |
| Plesinac et al, 2006 | 68 | 1 | 4 | 444 | 94.4 | 99.8 | NP |
| Chang et al, 2008   | 9    | 0    | 1    | 1190 | 90    | 100   | 3.5 MHz              |
| Chen et al, 2008    | 129  | 5    | 18   | 17,499 | 87.8   | 100   | 3.5 MHz              |
| Ren et al, 2008     | 33   | 2    | 21   | 11,488 | 61.1   | 99.9  | 3 MHz                |
| Ren et al, 2008     | 48   | 2    | 6    | 11,488 | 88.9   | 99.9  | 3 MHz                |
| Thangarooapan et al | 4    | 6    | 35   | 231  | 10.3  | 97.5  | 3.5, 7.5 MHz         |
| Wu et al, 2009      | 21   | 4    | 11   | 7989 | 65.6  | 99.9  | 3.5, 5.0 MHz         |
| Wu et al, 2009      | 26   | 4    | 6    | 7989 | 81.3  | 99.9  | 3.5–5 MHz            |
| Xu et al, 2009      | 50   | 1    | 23   | 4808 | 68.5  | 100   | 3.5, 5 MHz           |
| Bennasar et al, 2010 | 172 | 17 | 3 | 150 | 98.3 | 89.8 | 4–8 MHz |
| Huang et al, 2010   | 61   | 212  | 3    | 6224 | 95.3  | 96.7  | 1–5 MHz, 2–4 MHz     |
| Yan et al, 2010     | 37   | 4    | 6    | 4153 | 86.1  | 99.9  | 2–6 MHz              |
| Zhao et al, 2010    | 12   | 6    | 1    | 6602 | 92.3  | 99.9  | 4–6 MHz              |
| Yagel et al, 2011   | 169  | 0    | 24   | 12,908 | 87.6   | 100   | 5.0–12.0 MHz         |
| Abdul-Haïm et al, 2011 | 131 | 0 | 68 | 64,482 | 65.8 | 100 | NP |
| Zeng et al, 2011    | 9    | 0    | 5    | 279  | 64.3  | 100   | 4–5 MHz              |
| Prats et al, 2012   | 6    | 408  | 42   | 9027 | 12.5  | 95.7  | NP                   |
| Luan et al, 2012    | 37   | 0    | 4    | 9196 | 90.2  | 100   | 2–5 MHz, 1–5 MHz, 4–8 MHz |
| Wang et al, 2012    | 66   | 1    | 5    | 8409 | 93    | 100   | NP                   |
| Wang et al, 2012    | 35   | 1    | 5    | 3054 | 87.5  | 99.9  | 2.5–6 MHz            |
| Wang et al, 2014    | 13   | 2    | 2    | 1483 | 86.7  | 99.9  | NP                   |
| Wiechec et al, 2015 | 35   | 0    | 42   | 1007 | 45.7  | 100   | 4–8 MHz, 5–9 MHz     |

CHD = congenital heart disease, FN = false negatives, FP = false positives, NP = not provided, TN = true negatives, TP = true positives.
BCEE + OTV, and BCEE + OTV + 3VTV. We divided the eligible studies into 3 sections according to gestation order: the first trimester, the second trimester, the second to third trimester. And we also divided the eligible studies into 4 sections according to different risk factors: low risk, high risk, low and high risk, and unselected risk. The overall sensitivity of BCEE (Fig. 3A), BCEE + OTV (Fig. 3B), ECEE (Fig. 3C), BCEE + OTV + 3VTV (Fig. 3D) were 49.0%, 66.1%, 75.5%, and 83.7%, respectively. The overall sensitivity of ECEE, BCEE + OTV, and BCEE + OTV + 3VTV screening for fetal CHD was obviously higher compared with the echo-views of BCEE (Fig. 4) and ECEE (Fig. 5) screening for fetal CHD during the second to third trimester was obviously higher ($\chi^2 = 14.585$, $P < 0.05$, respectively). However, when compared with the second trimester, the overall sensitivity of BCEE + OTV and BCEE + OTV + 3VTV screening for fetal CHD during the second to third trimester was not statistically significant ($\chi^2 = 2.865$, $P = 0.091$, respectively).

To explore the sensitivity between the 4 scan protocols and 4 risk factors (low, high, low and high, unselected), we performed a layering research. In general, the overall sensitivity of BCEE, BCEE + OTV, ECEE, and BCEE + OTV + 3VTV for whole pregnancies were 49.0% (95% CI, 44.9%–53.2%), 66.1% (95% CI, 62.1%–70.0), 75.5% (95% CI, 73.2%–77.6%), and 83.7% (95% CI, 79.0%–87.7%), respectively. For pregnancies with low-risk factors and unselected factors, the overall sensitivity of BCEE (Fig. 6) was 36.1% (95% CI, 29.7%–42.9%) and 55.7% (95% CI, 49.1%–62.2%), respectively. Only one article studied BCEE for pregnancies with high-risk factors, and only 1 article studied BCEE for pregnancies with low and high factors. For pregnancies with low-risk factors and high risk factors (Fig. 7), the overall sensitivity of ECEE was 43.1% (95% CI, 38.5%–47.8%), 86.7% (95% CI, 83.2%–89.6%), and 89.5% (95% CI, 86.5%–92.0%), respectively. Only 2 articles studied ECEE for pregnancies with unselected factors. For pregnancies with low-risk factors and unselected factors, the overall sensitivity of BCEE + OTV was 63.1% (95% CI, 57.1%–68.9%) and 67.2% (95% CI, 61.1%–72.8%), respectively. Only 1 article studied BCEE + OTV for pregnancies with

![FIGURE 2. The SROC curve of echocardiography for the prenatal diagnosis of CHD. AUC = area under curve, CHD = congenital heart disease, SROC = summary receiver-operating characteristic.](image-url)
high risk-factors, but no article for low- and high-risk factors. Three articles discussed BCEE + OTV for pregnant women with unselected risk factors, the overall sensitivity was 77.4% (95% CI, 69.7%–83.9%).

Then a $\chi^2$ test was performed between 4 scan protocols and different risk factors. Compared with pregnancies with low risk factors, the overall sensitivity of BCEE for whole pregnancies was obviously higher ($\chi^2 = 10.605$, $P = 0.001$). Compared with pregnancies with low-risk factors, the overall sensitivity of ECEE for whole pregnancies was also higher ($\chi^2 = 133.827$, $P < 0.05$), and for pregnancies with high-risk factors and low- and high-risk factors, the overall sensitivity of ECEE was obviously higher when compared with whole pregnancies ($\chi^2 = 33.670$, 54.686, $P < 0.05$, respectively).

FIGURE 3. The pooled sensitivity and specificity of BCEE (A), BCEE + OTV (B), ECEE (C), BCEE + OTV + 3VTV (D) for the prenatal diagnosis of CHD. 3VTV = three vessel and trachea view, BCEE = basic cardiac echocardiographic examination, CHD = congenital heart disease; CI = confidence interval, ECEE = extended cardiac echocardiographic examination, OTV = outflow tract view.
However, the overall sensitivity of BCEE + OTV for whole pregnant women was not statistically significant than pregnancies with low-risk factors and unselected risk factors ($\chi^2 = 0.799, 0.069, P = 0.371, 0.793$, respectively). Compared with pregnancies with unselected risk factors, the overall sensitivity of BCEE + OTV + 3VT for whole pregnant women was not statistically significant ($\chi^2 = 1.963, P = 0.161$). Likewise, the overall sensitivity of BCEE was not statistically significantly than that of whole pregnancies ($\chi^2 = 2.998, P = 0.083$).
Sensitivity Analysis and Meta-Regression

There was substantial diversity across studies, the inconsistency ($I^2$) was 94.5%, and sensitivity was 68.5% (95% CI, 66.8%–70.2%). One set of study data, were systematically removed, and the pooled results for the remaining studies were rechecked whether the results had a significant change, the inconsistency was still between 94.0% and 94.6%, then we removed them all, the inconsistency was still 85%, which suggested that the sensitivity analysis was robust. Then the sensitivity analysis was conducted for every study. If substantial heterogeneity is found to be present, then reasons for such heterogeneity can be explored by relating study level covariates to an accuracy measure. So a meta-regression was performed, out of all of the parameters, the risk level was significant sources of heterogeneity ($P = 0.012$). However, none of the country, echo-view, transducer frequency, publication year, and gestation were statistically significant sources of heterogeneity ($P > 0.05$). The meta-regression analysis results were shown in Table 3.

TABLE 3. Meta-Regression (Inverse Variance Weights, n = 50)

| Var       | Coeff. | Std. Err. | $P$  | RDOR | 95% CI       |
|-----------|--------|-----------|-----|------|--------------|
| Cte.      | 3.933  | 2.0139    | 0.0575 | —    | —            |
| S         | −0.2575| 0.1623    | 0.0980 | —    | —            |
| Country   | −0.384 | 0.6173    | 0.5373 | 0.68 | (0.20, 1.96) |
| Echo-view | 0.026  | 0.3221    | 0.9359 | 1.03 | (0.54, 1.97) |
| Frequency | −0.003 | 0.0797    | 0.9715 | 1.00 | (0.85, 1.17) |
| Year      | 0.041  | 0.0612    | 0.5081 | 1.04 | (0.92, 1.18) |
| Gestation | 0.221  | 0.3496    | 0.5313 | 1.25 | (0.62, 2.52) |
| Risk level| 0.728  | 0.2775    | 0.0120 | 2.07 | (1.18, 3.63) |

CI = confidence interval.

Publication Bias

We used funnel plot to detect whether the potential the publication bias of included studies existed in this study. In funnel plots, each dot represents a study included. All dots symmetric distribution on both sides of the line suggested there was no obvious publication bias. If not, which indicated that publication bias was existed. An absence of any asymmetric distribution of data points in the funnel plot and a quantified result of $P = 0.061$ in the Deek test indicated no potential significant publication bias in our meta-analysis (Fig. 9).

DISCUSSION

The results of this meta-analysis indicate that prenatal echocardiography for CHD diagnosis had a moderate sensitivity and high specificity. The areas under the curve of the SROC curves for all data sets were $>0.9924$, which demonstrated a quite high diagnostic accuracy, regardless of the methodology variation and sample origin. It is reported that fetal echocardiography using as a clinical technique for the prenatal diagnosis of CHD was appeared in the early 1980s, and from then on numbers of studies aimed at assessing its accuracy for CHD. However, their results are inconsistent. Most future parents have great expectations from echocardiography screening for CHD and missed diagnoses often lead to legal action. Therefore, it is important to define the accuracy of echocardiography in pregnancies for CHD. Our study was designed for this purpose.

As the most basic ultrasound method, BCEE plays an important role in screening for fetal malformations. However, our study showed that the overall sensitivity and specificity were 49.0% and 99.9%, respectively. The overall sensitivity was lower compared with ECEE, BCEE + OTV, and BCEE + OTV + 3VTV, which increased chances of missed diagnosis. The reasons perhaps as follows: unclear image caused because of gestational age, limited resolution, transducer frequency, timing of examination, fetal position, and maternal factors; when the discrepancy of 4-chamber size is not obvious, such cardiac abnormalities as aortic coarctation and ventricular dysplasia maybe missed diagnosis; part of the cardiac abnormalities in pregnancy is progressive development, and they cannot be detected readily during the first and second trimester, such as aorta or pulmonary artery stenosis; part of the conotruncal defects manifest as normal 4-chamber size. In addition, we hold that the BCEE does not directly evaluate the great vessels, which is another important factor. We obtained a 66.1% sensitivity by BCEE + OTV, compared with 49.0% sensitivity with BCEE alone. Adding visualization of the ventricular outflow tracts to the assessment of the 4-chamber view has been suggested as likely to increase the sensitivity of ultrasound screening for major CHD. However, left and right ventricular outflow tract detection technology is not easy to master and to learn, and it is often time-consuming. To compensate for this weakness of BCEE, we added 3VTV to our routine fetal echocardiography protocol. Studies incorporating the 3VTV into screening obstetric examinations have also increased the detection of CHD. In our study, we obtained a sensitivity of 83.7% by BCEE + OTV + 3VTV. Addition of the outflow tracts and 3 vessels with trachea view can increase sensitivity...
We obtained a 75.5% sensitivity by ECEE and confirmed that ECEE had advantages in sensitivity ($\chi^2 = 133.14, P < 0.05$) compared with BCEE, so ECEE should be highlighted for fetal echocardiography.

Early screening of fetal CHD is vital for perinatal period health care and improving the prognosis of neonatal; furthermore, it can also promote the rapid development of fetal CHD treatment technology. What is more, earlier screening of fetal CHD can provide parents an opportunity to a safe termination of pregnancy or make a choice to karyotype analysis or genetic counseling. For parents who are at risk for having a CHD child, the finding of normal cardiac anatomy can relieve their anxious during early-stage per pregnancy. Even previous systematic review using 5 protocols detection of fetal CHD among unselected, low, high risk populations; however, they did not evaluate the sensitivity of different stages of pregnancy with different protocols. In our study, only 3 articles study the fetal CHD during the first trimester, so we could not make a specific comparison among different echocardiography protocols. The pooled sensitivity of the first trimester was 60.3%, compared with 77.4% of the second to third trimester; this is perhaps because of both the distance of the fetus from the maternal abdominal wall and the small size of the heart structures, so early fetal echocardiography should always be followed by echocardiography at second trimester and third trimester.

Our findings suggested that during the second trimester, BCEE and ECEE had a higher sensitivity of 47.4% and 58.4%, respectively. With the advancing of gestational age, the sensitivity of BCEE and ECEE increased to 65.6% and 84.9%, respectively. Although certain types of fetal CHD can be detected after 13 weeks of pregnancy, fetal echocardiography for screening of pregnancies at risk for CHD generally should be performed at 18 to 22 weeks of gestation.

Our finding suggested that, compared with the low risk population by BCEE, the unselected risk population received more benefit from screening of fetal CHD. Likewise, the high-risk, low- and high-risk population received more benefit from prenatal fetal CHD screening when compared with unselected populations. However, for BCEE + OTV and BCEE + OTV + 3TV, they did not receive more benefit from prenatal screening ($P > 0.05$). We also find that, compared with BCEE among the low-risk populations, ECEE yielded a higher sensitivity, similarity, when compared with low-risk populations and ECEE for high-risk populations yielded a higher sensitivity, which perhaps because the pregnant women with high-risk factors had a high risk of delivering a fetus with CHD. Thus, ECEE had a higher sensitivity compared with BCEE; this result coincides with the results of previous meta-analysis. However, there were only 23 prospective studies in their meta-analysis, whereas 50 prospective studies were involved in our meta-analysis. According to the regression analysis results, we find that among all related variables, the risk levels were an independent predictor of the sensitivity of a CHD diagnosis. Inevitably, there are also some limitations in this meta-analysis. Our study was based on pooled data; substantial variation will continue to exist, despite any subgroup analysis. Besides, the power to detect differences among subgroups may have been limited by the small number of studies in specific subgroups.

CONCLUSIONS

In conclusion, our study has shown it is highly effective to perform prenatal fetal CHD echocardiography screening for its moderate sensitivity and particularly higher specificity. We also find that with the population risk factor advances, progression in gestational age, extension of the echo-views, combination of echocardiographic approaches, and promotion of the echocardiographic modality, the diagnostic sensitivity of fetal CHD was significantly increased. Furthermore, prenatal fetal CHD echocardiography screening result should not based on any single ultrasonic modality. As a result of the limitation of literature relevant, further large-scale multicenter prospective studies are warranted.
REFERENCES

1. Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation. 2014;129:2183–2242.

2. Rosano A, Botto LD, Botting B. Infant mortality and congenital anomalies from 1950 to 1994: an international perspective. J Epidemiol Community Health. 2000;54:660–666.

3. Franklin O, Burch M, Manning N, et al. Prenatal diagnosis of coarctation of the aorta improves survival and reduces morbidity. Heart. 2002;87:67–69.

4. American Institute of Ultrasound in Medicine. AIUM practice guideline for the performance of fetal echocardiography. J Ultrasound Med. 2013;32:1067–1082.

5. DeVore G, Medearis AL, Bear MB, et al. Fetal echocardiography: factors that influence imaging of the fetal heart during the second trimester of pregnancy. J Ultrasound Med. 1993;12:659–663.

6. Sharland GK, Allan LD. Screening for congenital heart disease prenatally. Results of a 2 1/2-year study in the South East Thames Region. Br J Obstet Gynaecol. 1992;99:220–225.

7. Achiron R, Glaser J, Gelernter I, et al. Extended fetal echocardiographic examination for detecting cardiac malformations in low risk pregnancies. BMJ. 1992;304:671–674.

8. Fetal Echocardiography Task Force; American Institute of Ultrasound in Medicine Clinical Standards Committee; American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. AIUM practice guideline for the performance of fetal echocardiography. J Ultrasound Med. 2013;32:1067–1082.

9. Lee W, Allan L, Carvalho JS, et al. ISUOG consensus statement: what constitutes a fetal echocardiogram? Ultrasound Obstet Gynecol. 2008;32:239–242.

10. Rychik J, Ayres N, Cuneo B, et al. American Society of Echocardiography guidelines and standards for performance of the fetal echocardiogram. J Am Soc Echocardiogr. 2004;17:803–810.

11. Allan L, Dangel J, Fesslova V, et al. Recommendations for the practice of fetal cardiology in Europe. Cardiol Young. 2004;14:109–114.

12. Ott WJ. The accuracy of antenatal fetal echocardiography screening in high- and low-risk patients. Am J Obstet Gynecol. 1995;172:1741–1747.

13. Buskens E, Grobbee DE, Frohn-Mulder IM, et al. Efficacy of routine fetal ultrasound screening for congenital heart disease in normal pregnancy. Circulation. 1996;94:67–72.

14. Zosmer N, Souter VL, Chan CS, et al. Early diagnosis of major cardiac defects in chromosomally normal fetuses with increased nuchal translucency. Br J Obstet Gynaecol. 1999;106:829–833.

15. Oggé G, Gaglioti P, Maccanti S, et al. Prenatal screening for congenital heart disease with four-chamber and outflow-tract views: a multicenter study. Ultrasound Obstet Gynecol. 2006;28:779–784.

16. Tegnander E, Williams W, Johansen OJ, et al. Prenatal detection of heart defects in a non-selected population of 30,149 fetuses–detection rates and outcome. Ultrasound Obstet Gynecol. 2006;27:252–265.

17. Abu-Rustum RS, Dauo L, Abu-Rustum SE. Role of first-trimester sonography in the diagnosis of aneuploidy and structural fetal anomalies. J Ultrasound Med. 2010;29:1445–1452.

18. Li Y, Hua Y, Fang J, et al. Performance of different scan protocols of fetal echocardiography in the diagnosis of fetal congenital heart disease: a systematic review and meta-analysis. PLoS One. 2013;8:e65484.

19. Levi S, Hyjazi Y, Schaapst JP, et al. Sensitivity and specificity of routine antenatal screening for congenital anomalies by ultrasound. the Belgian Multicentric Study. 1991;1:102–110.

20. Luck CA. Value of routine ultrasound scanning at 19 weeks: a four year study of 8849 deliveries. BMJ. 1992;304:1474–1478.

21. Vergani P, Mariani S, Ghidini A, et al. Screening for congenital heart disease with the four-chamber view of the fetal heart. Am J Obstet Gynecol. 1992;167:1000–1003.

22. Achiron R, Weissman A, Rotstein Z, et al. Transvaginal echocardiographic examination of the fetal heart between 13 and 15 weeks’ gestation in a low-risk population. J Ultrasound Med. 1994;13:783–789.

23. Kirk JS, Riggs TW, Comstock CH, et al. Prenatal screening for cardiac anomalies: the value of routine addition of the aortic root to the four-chamber view. Obstet Gynecol. 1994;84:427–431.

24. Hsieh CC, Kuo DM, Chiu TH, et al. Prenatal diagnosis of major congenital cardiovascular malformations. Gynecol Obstet Invest. 1996;42:84–87.

25. Zhou QC, Tan HY, Lu SK. The clinical value of fetal congenital heart disease diagnosed by color Doppler echocardiography. Chin J Obstet Gynecol. 1996;31:474–476.

26. Kirk JS, Comstock CH, Lee W, et al. Sonographic screening to detect fetal cardiac anomalies: a 5-year experience with 111 abnormal cases. Obstet Gynecol. 1997;89:227–232.

27. Todros T, Faggiano F, Chiappa E, et al. Accuracy of routine ultrasonography in screening heart disease prenatally. Prenat Diagn. 1997;17:901–906.

28. Stefos T, Plachouras N, Sotiriadis A, et al. Routine obstetrical ultrasound at 18-22 weeks: our experience on 7,236 fetuses. J Matern Fetal Med. 1999;8:64–69.

29. Pan W, Wu GP, Li YF. The experience of diagnosing congenital heart disease by fetal echocardiography on 900 fetus. South China J Cardiovasc Dis. 2001;7:180–182.

30. Comas Gabriel C, Galindo A, Martinez JM, et al. Early prenatal diagnosis of major cardiac anomalies in a high-risk population. Prenat Diagn. 2002;22:586–593.

31. Ozkutlu S, Ayabakan C, Karagoz T, et al. Prenatal echocardiographic diagnosis of congenital heart disease; comparison of past and current results. Turk J Pediatr. 2005;47:232–238.

32. Zhou QC, Zhang J, Zhang M, et al. Utilising ductus venous Doppler waveform and four-chamber view to screen for foetal cardiac malformation in early second trimester of pregnancy. Chin Med J. 2005;118:1791–1796.

33. Liu YY, Lu GR, Li BY, et al. Comparative study on prenatal ultrasonographic methods in screening for fetal congenital heart disease. Chin J Med Ultrasound. 2005;2:353–355.

34. Becker R, Wegner RD. Detailed screening for fetal anomalies and cardiac defects at the 11–13-week scan. Ultrasound Obstet Gynecol. 2006;27:613–618.

35. Zhu RY, Gui YH, Li LC, et al. Fetal echocardiography in diagnosing congenital heart disease prenatally: a multicenter clinical study. Chin J Pediatr. 2006;44:764–769.

36. Plesinac S, Terzic M, Stimac B, et al. Value of fetal echocardiography in diagnosis of congenital heart disease in a Serbian university hospital. Int J Fertil Womens Med. 2007;52:89–92.

37. Chang HM, Deng XD, Si RH, et al. Fetal echocardiography in detecting fetal congenital heart disease. Chin J Med Imaging Technol. 2008;24:1099–1101.

38. Chen QY, Lu GR, Li BY. Prenatal sonography for the detection of fetal cardiac anomalies: with 147 abnormal cases. Chinese J Ultrasound Med. 2008;24:935–938.

39. Ren YY, Li XT, Gui YH, et al. evaluation of the prenatal screening mode for fetal congenital heart disease by ultrasound. Chin J Obstet Gynecol. 2008;43:589–592.
40. Thangaroopan M, Wald RM, Silversides CK, et al. Incremental diagnostic yield of pediatric cardiac assessment after fetal echocardiography in the offspring of women with congenital heart disease: a prospective study. *Pediatrics*. 2008;121:e660–e665.

41. Wu Q, Li M, Ju L, et al. Application of the 3-vessel view in routine prenatal sonographic screening for congenital heart disease. *J Ultrasound Med*. 2009;28:1319–1324.

42. Xu Y, Hu YL, Ru T, et al. Importance of “Guidelines for performing fetal cardiac scan” in prenatal screening for congenital heart disease. *China J Obstet Gynecol*. 2009;44:103–107.

43. Bennasar M, Martinez JM, Gomez O, et al. Accuracy of four-dimensional spatiotemporal image correlation echocardiography in the prenatal diagnosis of congenital heart defects. *Ultrasound Obstet Gynecol*. 2010;36:458–464.

44. Huang ZP, Liao P, Liu L, et al. Diagnosis and analysis of fetal congenital heart disease by color Doppler echocardiography. *Chinese J Med*. 2010;45:33–35.

45. Yan HL, Yan RL, Hou M. Preliminary study of ultrasonographic 4-vessel view in routine prenatal sonographic screening for congenital heart disease. *J Ultrasound Med*. 2009;5:43–44.

46. Zhao WJ, Yin WH, Xiao MH. Preliminary study of ultrasonographic methods in screening for fetal congenital heart disease. *China Prac Med*. 2010;5:43–44.

47. Yagel S, Cohen SM, Rosenak D, et al. Added value of three-/four-dimensional ultrasound in offline analysis and diagnosis of congenital heart disease. *Ultrasound Obstet Gynecol*. 2011;37:432–437.

48. Zeng HY, Shao RB, Zhao Y. The clinical value of four-chamber view on the fetal congenital heart disease screening. *Guang Zhou Med J*. 2011;42:27–28.

49. Prats P, Ferrer Q, Comas C, et al. Is the addition of the ductus venous useful when screening for aneuploidy and congenital heart disease in fetuses with normal nuchal translucency? *Fetal Diagn Ther*. 2012;32:138–143.

50. Luan ZD, Zhang XP, Liu YQ, et al. Clinical value of the ultrasound screening using five views in fetal congenital heart disease. *J Med Imag*. 2012;22:1449–1454.

51. Wang CL, Zhou X. Study the clinical value of echocardiography for prenatal diagnosis of fetal congenital heart disease. *HeiBei Med*. 2012;18:740–742.

52. Wang F. Diagnostic value of echocardiography in the diagnosis of congenital heart disease in fetus. *MMJC*. 2012;14:63–64.

53. Wang MF, Liu DP, Zhang GZ. Clinical value of echocardiography screening for congenital heart disease. *Chinese J Med Guide*. 2014;16:1218–1219.

54. Wiechec M, Knafel A, Nocun A. Prenatal detection of congenital heart defects at the 11- to 13-week scan using a simple color Doppler protocol including the 4-chamber and 3-vessel and trachea views. *J Ultrasound Med*. 2015;34:585–594.

55. Grandjean H, Larroque D, Levi S. The performance of routine ultrasonographic screening of pregnancies in the Eurofetus Study. *Am J Obstet Gynecol*. 1999;181:446–454.

56. Chauvi R, McEwin R. Three cross-sectional planes for fetal color Doppler echocardiography. *Ultrasound Obstet Gynecol*. 2003;21:81–93.

57. Rustico MA, Benettoni A, Dottavio G, et al. Fetal heart screening in low-risk population. *Ultrasound Obstet Gynecol*. 1995;6:313–319.

58. Yu ZB, Han SP, Guo XR. Meta-analysis of the value of fetal echocardiography for the prenatal diagnosis of congenital heart disease. *Chin J Evid Based Pediatr*. 2009;4:330–339.

59. Yoo SJ, Lee YH, Kim ES. Three-vessel view of the fetal upper mediastinum: an easy means of detecting abnormalities of the ventricular outflow tracts and great arteries during obstetric screening. *Ultrasound Obstet Gynecol*. 1997;9:173–182.

60. Del Bianco A, Russo S, Lacerenza N, et al. Four chamber view plus three-vessel and trachea view for a complete evaluation of the fetal heart during the second trimester. *J Perinat Med*. 2006;34:309–312.

61. Marek J, Tomek V, Skovranek J, et al. Prenatal ultrasound screening of congenital heart disease in an unselected national population: a 21-year experience. *Heart*. 2011;97:124–130.

62. Hartge DR, Weichert J, Krap M, et al. Results of early foetal echocardiography and cumulative detection rate of congenital heart disease. *Cardiol Young*. 2011;21:505–517.

63. Persico N, Moratala J, Lombardi CM, et al. Fetal echocardiography at 11-13 weeks by transabdominal high-frequency ultrasound. *Ultrasound Obstet Gynecol*. 2011;37:296–301.

64. Gembuch U, Shi C, Smrecek J. Biomety of the fetal heart between 10 and 17 weeks’ gestation. *Fetal Diagn Ther*. 2000;15:20–31.

65. Fong K, Toi A, Salem S. Detection of fetal structural abnormalities with US during early pregnancy. *Radiographics*. 2004;24:157–174.

66. International Society of Ultrasound in Obstetrics and Gynecology. Cardiac screening examination of the fetus: guidelines for performing the ‘basic’ and ‘extended basic’ cardiac scan. *Ultrasound Obstet Gynecol*. 2006;27:107–113.

67. Rasiah SV, Publicover M, Ewer AK. A systematic review of the accuracy of first-trimester ultrasound examination for detecting major congenital heart disease. *Ultrasound Obstet Gynecol*. 2006;28:110–116.